Abstract
Unveiling the pathologic predictor in patients with metastatic hormone-sensitive prostate cancer treated with abiraterone: Intraductal carcinoma of the prostate and its subtypes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have